Current issue #13, 2016

Spy bridge

Professional associations to play foreign agents

PharmVestnik analyzed draft amendments to the Federal law # 7 (FZ-7) “On nonprofit organizations” in respect of specifying the concept of “political activities” and came to a curious conclusion. If the law is adopted, there is a high degree of probability that charity foundations and the most part of professional pharma associations will find themselves among foreign agents. At that, these may be not only associations comprising foreign companies or citizens but also local organizations with offshore founders.

[PharmVestnik # 13, 12/04/2016, p. 1, cont’d p. 3]

Hostages of interchangeability

Professional community believes that sticking point of interchangeability shall not act as a brake on EEU common market launch

The Federal Antimonopoly Service (FAS) activity in promoting the term “interchangeability” into the regulatory environment of the Russia Federation has borne first fruit. It is this term that has become the stumbling block in the process of reviewing the documents on the EEU common market. None of the EEU member states agree with Russia’s arguments. The professional community has split into two parties in forecasting whose side was going to win. In the end of March, at a relevant conference, it was for the first time proposed to remove this term from the national legislation as the FAS do not have any authority to establish interchangeability. In its turn, the antimonopoly agency is ready to press its point and keep ground.

[PharmVestnik # 13, 12/04/2016, p. 2]

Doing a disservice

Russian pharmaceutical manufacturers treat FAS’ initiatives with reserve

The beginning of 2016 has given rise to a lot of regulatory initiatives in the pharmaceutical industry – from the EEU common market currently pending resolution to the draft law permitting drug sales at supermarkets. Therefore, the roundtable discussion on healthcare innovations within the framework of the InfoSpace innovative technology forum focused mainly on regulatory novelties. It turned out that not all of the regulatory initiatives were indisputable.

[PharmVestnik # 13, 12/04/2016, p. 4]

Minpromtorg overdid looking for Pharm-Sintez’ violations

On April 4, pursuant to court judgment, JSC Pharm-Sintez...